

Nombre: María del Monte Millán

Posición actual: Coordinadora de Estudios Traslacionales

Áreas de investigación:

Oncología. Investigación traslacional.

Área 6. Grupo de Oncología Traslacional Instituto Investigación Biomédica Hospital General Universitario Gregorio Marañón

Formación Académica más destacada:

Diploma de Estudios Avanzados en BIOQUIMICA Y BIOLOGÍA MOLECULAR (Universidad Autónoma de Madrid, 2002-2004).

Licenciatura en Ciencias Biológicas en la especialidad de BIOQUIMICA Y BIOLOGÍA MOLECULAR (Universidad Autónoma de Madrid, 1994-2000).

Otras áreas de desarrollo profesional:

Número total de artículos: 22

Número de capítulos de libros: 2

Comunicaciones a congresos: 39

Número de patentes: 13

Colaboración en proyectos de investigación financiados por entidades públicas y privadas

Participación en actividades formativas (TFGM y Tesis)

Pertenencia a redes de investigación y sociedades

- RETICS (Redes Temáticas de Investigación Cooperativa en Salud) en el área de Cáncer 2014-2016
- CIBER (2016, CB16/12/00471) Thematic area: Cancer. Topic: Development of new targeted and immune therapies for luminal, HER2-positive and /or triple negative breast cancer therapies
- Sociedad Española de Oncología Médica (SEOM)
- Asociada del Grupo español de Investigación en cáncer de mama (GEICAM)

Publicaciones más relevantes últimos años en cáncer:

1. Ramos-Medina, R et al. TECHNICAL CHALLENGES FOR CTC IMPLEMENTATION IN BREAST CANCER. *Cancers* 2021, 13, 4619. <https://doi.org/10.3390/cancers13184619>
2. Martín, M. et al. ACTIVITY OF DOCETAXEL, CARBOPLATIN, AND DOXORUBICIN IN PATIENT-DERIVED TRIPLE-NEGATIVE BREAST CANCER XENOGRAFTS. *Scientific reports*, 11(1), 7064 (2021). <https://doi.org/10.1038/s41598-021-85962-4>
3. Escudero-Vilaplana V et al. ASSESSMENT OF DIARRHEA AS SIDE EFFECT OF ORAL TARGETED ANTINEOPLASTIC AGENTS IN CLINICAL PRACTICE. *Support Care Cancer*. 2021 Jan 28. doi: 10.1007/s00520-021-06016-z. Epub ahead of print. PMID: 33506273.
4. Laria, J.C. et al. ITERATIVE VARIABLE SELECTION FOR HIGH-DIMENSIONAL DATA: PREDICTION OF PATHOLOGICAL RESPONSE IN TRIPLE-NEGATIVE BREAST CANCER. *Mathematics* 2021, 9, 222. <https://doi.org/10.3390/math9030222>.
5. Antonio Calles et al. OUTCOMES OF COVID-19 IN PATIENTS WITH LUNG CANCER TREATED IN A TERTIARY HOSPITAL IN MADRID. *Front. Oncol.*, 16 September 2020 <https://doi.org/10.3389/fonc.2020.01777>
6. Rocío Núñez-Torres et al., ASSOCIATION BETWEEN ABCB1 GENETIC VARIANTS AND PERSISTENT CHEMOTHERAPY-INDUCED ALOPECIA IN WOMEN WITH BREAST CANCER. *JAMA Dermatol*. Published online August 05, 2020. doi:10.1001/jamadermatol.2020.1867
7. Sara Pérez Ramírez et al. PROSPECTIVE, MULTICENTER STUDY ON THE ECONOMIC AND CLINICAL IMPACT OF GENE EXPRESSION ASSAYS IN EARLY STAGE BREAST CANCER FROM A SINGLE REGION: THE

- PREGECAM REGISTRY EXPERIENCE. *Clin Transl Oncol* 22, 717–724 (2020). <https://doi.org/10.1007/s12094-019-02176-x>
8. A Picornell et al. BREAST CANCER PAM50 SIGNATURE: CORRELATION AND CONCORDANCE BETWEEN RNA-SEQ AND DIGITAL MULTIPLEXED GENE EXPRESSION TECHNOLOGIES. *BMC Genomics* (2019) 20:452 <https://doi.org/10.1186/s12864-019-5849-0>
 9. Fernando Moreno et al., CONCORDANCE OF GENOMIC VARIANTS IN MATCHED PRIMARY BREAST CANCER, METASTATIC TUMOR, AND CIRCULATING TUMOR DNA: THE MIRROR STUDY” *JCO Precision Oncology* 2019 DOI: 10.1200/PO.18.00263 Published online May 10, 2019
 10. Priyanka Sharma et al., PATHOLOGICAL RESPONSE AND SURVIVAL IN TRIPLE-NEGATIVE BREAST CANCER FOLLOWING NEOADJUVANT CARBOPLATIN PLUS DOCETAXEL. *Clinical Cancer Research* Published OnlineFirst on July 30, 2018; DOI: 10.1158/1078-0432.CCR-18-0585
 11. Echavarría I et al., PATHOLOGICAL RESPONSE IN A TRIPLE NEGATIVE BREAST CANCER COHORT TREATED WITH NEOADJUVANT CARBOPLATIN AND DOCETAXEL ACCORDING TO LEHMANN'S REFINED CLASSIFICATION. *Clinical Cancer Research*. 2018 Jan 29. pii: clincanres.1912.2017. doi: 10.1158/1078-0432.CCR-17-1912. [Epub ahead of print]
 12. Priyanka Sharma et al., EFFICACY OF NEOADJUVANT CARBOPLATIN PLUS DOCETAXEL IN TRIPLE NEGATIVE BREAST CANCER: COMBINED ANALYSIS OF TWO COHORTS. *CLINICAL CANCER RESEARCH*. First online: June 15, 2016
 13. Milagros Gonzalez-Rivera et al., FREQUENCY OF GERMLINE DNA GENETIC FINDINGS IN AN UNSELECTED PROSPECTIVE COHORT OF TRIPLE-NEGATIVE BREAST CANCER PATIENTS PARTICIPATING IN A PLATINUM-BASED NEOADJUVANT CHEMOTHERAPY TRIAL. *Breast Cancer Research and Treatment*, (), 1-9. First online: 15 April 2016. DOI 10.1007/s10549-016-3792-1
 14. R. Ramos-Medina et al., REVIEW: CIRCULATING TUMOR CELLS IN THE PRACTICE OF BREAST CÁNCER ONCOLOGY. *Clin Transl Oncol*. 2015. DOI 10.1007/s12094-015-1460-2 Published online: 08 December 2015